Involvement of Ion Channels in Endothelin-1-induced Signalling in Human Prostate Cancer Cells

Vancauwenberghe, Eric; Lallet-Daher, Hélène; Derouiche, ra; Mariot, Pascal; Gosset, Pierre; Delcourt, Philippe; Mauroy, Brigitte; Bonnal, J; Allart, Laurent; Prevarskaya, Natalia; Roudbaraki, Morad

doi:10.4172/2576-1471.1000126

Cited by 1 publication

(1 citation statement)

References 62 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of negative feedback in growth factor signaling pathways is to generate stability, limiting the duration and extent of signaling and preventing potentially harmful overactivation of signaling (51). However, we observed overexpression of endothelin-1 (ET-1), which can be a compensatory cellular mechanism that acts alone or in cooperation with other tyrosine kinase growth factors, such as PDGFR and VEGFR, to activate RTKs, leading to cell proliferation and angiogenesis (52)(53)(54)(55). Signaling pathways require both positive and negative feedback loops to adjust their cellular response; these feedback loops act through different genes, mechanisms, and stimuli (56).…”

Section: Discussionmentioning

confidence: 97%

Transcriptome of Two Canine Prostate Cancer Cells Treated With Toceranib Phosphate Reveals Distinct Antitumor Profiles Associated With the PDGFR Pathway

et al. 2020

View full text Add to dashboard Cite

Canine prostate cancer (PC) presents a poor antitumor response, usually late diagnosis and prognosis. Toceranib phosphate (TP) is a nonspecific inhibitor of receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. This study aimed to evaluate VEGFR2, PDGFR-β, and c-KIT protein expression in two established canine PC cell lines (PC1 and PC2) and the transcriptome profile of the cells after treatment with TP. Immunofluorescence (IF) analysis revealed VEGFR2 and PDGFR-β protein expression and the absence of c-KIT protein expression in both cell lines. After TP treatment, only the viability of PC1 cells decreased in a dose-dependent manner. Transcriptome and enrichment analyses of treated PC1 cells revealed 181 upregulated genes, which were related to decreased angiogenesis and cell proliferation. In addition, we found upregulated PDGFR-A, PDGFR-β, and PDGF-D expression in PC1 cells, and the upregulation of PDGFR-β was also observed in treated PC1 cells by qPCR. PC2 cells had fewer protein-protein interactions (PPIs), with 18 upregulated and 22 downregulated genes; the upregulated genes were involved in the regulation of parallel pathways and mechanisms related to proliferation, which could be associated with the resistance observed after treatment. The canine PC1 cell line but not the PC2 cell line showed decreased viability after treatment with TP, although both cell lines expressed PDGFR and VEGFR receptors. Further studies could explain the mechanism of resistance in PC2 cells and provide a basis for personalized treatment for dogs with PC.

show abstract